GMP News and Research

RSS

NCMC develops national roadmap for large-scale manufacturing of cell-based therapeutics

An industry-driven consortium has developed a national roadmap designed to chart the path to large-scale manufacturing of cell-based therapeutics for use in a broad range of illnesses including cancer, neuro-degenerative diseases, blood and vision disorders and organ regeneration and repair.

15 Jun 2016

ProBioGen will license GlymaxX® to Thermo Fisher Scientific for use in developing allergy diagnostics

ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins and corresponding technologies, today announced that Thermo Fisher Scientific has licensed its GlymaxX® technology for use in development of allergy diagnostics.

19 May 2016

Pluristem completes enrollment in Phase II intermittent claudication trial

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded (PLX)-PAD cells for the treatment of intermittent claudication (IC), a peripheral artery disease (PAD). The double blind, randomized, placebo controlled trial enrolled 50 patients since October 2015 in the U.S., Germany, Israel, and South Korea.

16 May 2016

Bruker showcases new products, analytical solutions for improved performance at Analytica 2016

This week at Analytica 2016, Bruker is showcasing new products and analytical solutions for improved performance and customer experience in pharmaceutical, industrial and applied markets.

From Bruker BioSpin Division 11 May 2016

ITL Virginia successfully completes three years of operation

Monday, 1 May will see ITL celebrate an important milestone, as the company marks three years since launching its US operation, ITL Virginia.

From Vitl Life Science Solutions 5 May 2016

Researchers to discuss on innovative cellular therapies during EBMT meeting

Cellular Therapy is an emerging medical science that is today facing a unique developmental phase, well documented by the outstanding and growing numbers of clinical trials.

30 Mar 2016

BioAgilytix announces acquisition of IPM Biotech

BioAgilytix, a leading provider of contract bioanalytical testing services specializing in large molecule bioanalysis, has announced the acquisition of IPM Biotech, a German-based bioanalytical contract research laboratory renowned for its expertise in large molecule bioanalysis, particularly in the area of immunogenicity.

18 Mar 2016

Bruker showcases innovative NMR solutions for pharmaceutical industry at ENC 2015

At the 56th Experimental Nuclear Magnetic Resonance Conference, Bruker this week is show-casing several innovative drug discovery, drug development and process control solutions for small molecule NMR characterization in the pharmaceutical industry.

From Bruker BioSpin Division 15 Mar 2016

New drug could transform treatment of metastatic triple negative breast cancer

A team of investigators from Houston Methodist Research Institute may have transformed the treatment of metastatic triple negative breast cancer by creating the first drug to successfully eliminate lung metastases in mice.

15 Mar 2016

China Biologic's total sales increase by 22.6% in RMB terms to $68.3 million in Q4 2015

China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2015.

26 Feb 2016

PolyPid closes $22 million private equity financing

PolyPid Ltd., an emerging clinical-stage specialty pharmaceutical company, focused primarily on the development of post-surgical anti-infection pipeline, announced today that it closed a $22 million private equity financing.

24 Feb 2016

New €5.6 million project aims to develop cell-based haemophilia A therapy

Loughborough University is working with a team of international partners on a new €5.6 million project to develop a cell based haemophilia A therapy.

25 Jan 2016

Jubilant Biosys, Sanofi partner to develop small molecule inhibitors in metabolic disorders therapeutic area

Jubilant Biosys Ltd, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd, and Sanofi Deutschland GmbH, Frankfurt, Germany, announced a strategic alliance to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area.

7 Jan 2016

CFDA issues new drug certificate and production license for Sinovac's EV71 vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that the China Food and Drug Administration issued the new drug certificate and production license for its Enterovirus 71 ("EV71") vaccine.

4 Jan 2016

New $8.5M research grant aims to address patients affected by severe hemophilia A

People with hemophilia have prolonged abnormal bleeding as a result of trauma. Hemophilia A, also called factor VIII (FVIII) deficiency, is the most common form of the genetic disorder caused by missing or defective blood clotting protein called factor VIII.

23 Dec 2015

Videregen-led TETRA consortium awarded EUR 6.8 million for pivotal Phase II trial of replacement trachea

The pan-European TETRA consortium, led by Videregen Limited, has been awarded EUR 6.8 million under the Horizon 2020 programme for a pivotal Phase II clinical trial of the company's tissue engineered replacement trachea.

10 Dec 2015

Ajinomoto Althea expands biological drug product manufacturing operations

Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs).